PE20040834A1 - ISOMEROS POSICIONALES DEL IFN PEG ALFA 2a - Google Patents

ISOMEROS POSICIONALES DEL IFN PEG ALFA 2a

Info

Publication number
PE20040834A1
PE20040834A1 PE2003001148A PE2003001148A PE20040834A1 PE 20040834 A1 PE20040834 A1 PE 20040834A1 PE 2003001148 A PE2003001148 A PE 2003001148A PE 2003001148 A PE2003001148 A PE 2003001148A PE 20040834 A1 PE20040834 A1 PE 20040834A1
Authority
PE
Peru
Prior art keywords
lys
peg
interferon
sticked
alpha
Prior art date
Application number
PE2003001148A
Other languages
English (en)
Inventor
Alfred Schacher
Doris Brugger
Stefan Foser
Karl Weyer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20040834A1 publication Critical patent/PE20040834A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A ISOMEROS POSICIONALES DEL INTERFERON ALFA 2a PEGILADO SELECCIONADO DEL GRUPO INTERFERON ALFA 2a PEGILADO A Lys(31) (PEG-Lys(31)), INTERFERON ALFA 2a PEGILADO A Lys(49) (PEG-Lys(49)), INTERFERON ALFA 2a PEGILADO A Lys(70) (PEG-Lys(70)), INTERFERON ALFA 2a PEGILADO A Lys(83) (PEG-Lys(83)), INTERFERON ALFA 2a PEGILADO A Lys(112) (PEG-Lys(112)), INTERFERON ALFA 2a PEGILADO A Lys(121) (PEG-Lys(121)), INTERFERON ALFA 2a PEGILADO A Lys(131) (PEG-Lys(131)), INTERFERON ALFA 2a PEGILADO A Lys(134), (PEG-Lys(134)), E INTERFERON ALFA 2a PEGILADO A Lys(164) (PEG-Lys(164)); EN DONDE DICHOS ISOMEROS ESTAN CARACTERIZADOS PORQUE EL PESO MEDIO MOLECULAR DE LA PORCION DE POLIETILENGLICOL (PORCION PEG) ES DE ALREDEDOR DE 26,000 A 66,000 DALTONS, ESPECIALMENTE 40000 DALTONS. TAMBIEN SE REFIERE A UN METODO PARA EL AISLAMIENTO DE ESTOS ISOMEROS POSICIONALES DEL INTERFERON ALFA 2a PEGILADO CARACTERIZADO PORQUE EL INTERFERON PEGILADO ES: a) SEPARADO EN SUS ISOMEROS POSICIONALES SOBRE UNA COLUMNA DE CROMATOGRAFIA LIQUIDA PREPARATIVA CON UNA MATRIZ DE INTERCAMBIO DE CATION DEBIL Y b) LAS FRACCIONES SE SEPARARON POSTERIORMENTE Y PURIFICARON SOBRE UNA COLUMNA PREPARATIVA CON UNA MATRIZ DE INTERCAMBIO CATIONICO. SE REFIERE TAMBIEN A UN COMPOSICION FARMACEUTICA QUE LOS CONTIENE. DICHOS ISOMEROS POSICIONALES DEL INTERFERON ALFA 2a SON UTILES PARA EL TRATAMIENTO O PROFILAXIS DE DISFUNCIONES INMUNOMODULATORIAS O EN EL TRATAMIENTO DE ENFERMEDADES VIRALES
PE2003001148A 2002-11-15 2003-11-13 ISOMEROS POSICIONALES DEL IFN PEG ALFA 2a PE20040834A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02025585 2002-11-15

Publications (1)

Publication Number Publication Date
PE20040834A1 true PE20040834A1 (es) 2004-11-17

Family

ID=32319537

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003001148A PE20040834A1 (es) 2002-11-15 2003-11-13 ISOMEROS POSICIONALES DEL IFN PEG ALFA 2a

Country Status (23)

Country Link
US (1) US20040223950A1 (es)
EP (1) EP1562634B1 (es)
JP (1) JP4279258B2 (es)
KR (1) KR20050065677A (es)
CN (1) CN1323722C (es)
AR (1) AR042039A1 (es)
AT (1) ATE337017T1 (es)
AU (1) AU2003293668A1 (es)
BR (1) BR0316227A (es)
CA (1) CA2503594C (es)
DE (1) DE60307881T2 (es)
ES (1) ES2270152T3 (es)
GT (1) GT200300244A (es)
MX (1) MXPA05005178A (es)
NO (1) NO20052310L (es)
PA (1) PA8587801A1 (es)
PE (1) PE20040834A1 (es)
PL (1) PL376883A1 (es)
RU (1) RU2005118752A (es)
TW (1) TW200413404A (es)
UY (1) UY28080A1 (es)
WO (1) WO2004045648A1 (es)
ZA (1) ZA200503756B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
NZ540043A (en) * 2002-11-18 2007-11-30 Maxygen Inc Isolated or recombinant Interferon-alpha polypeptides and conjugates
AU2005211385B2 (en) 2004-02-02 2008-12-11 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
WO2005113592A2 (en) * 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
BRPI0609809A2 (pt) 2005-05-18 2011-10-11 Maxygen Inc polipeptìdeo isolado ou recombinante, conjugado, composição, polinucleotìdeo isolado ou recombinante, célula hospedeira, vetor, métodos para preparar o polipeptìdeo, para preparar um conjugado, para inibir replicação de um vìrus em células infectadas com o vìrus para reduzir o numero de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna de hcv no soro de um paciente infectado com hcv, para reduzir o nìvel de dna de hbv em soro de um paciente infectado com hbv e para reduzir o nìvel de rna de hiv em soro de um paciente infectado com hiv, e, uso do polipeptìdeo ou do conjugado
US7695710B2 (en) 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
AU2006262151A1 (en) * 2005-06-20 2007-01-04 Pepgen Corporation Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau
CN101002944B (zh) * 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
AR078117A1 (es) * 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
EP2196475B1 (en) * 2007-09-04 2012-06-06 Biosteed Gene Expression Tech. CO., LTD. INTERFERON ALPHA 2a MODIFIED BY POLYETHYLENE GLYCOL, ITS SYNTHESIS PROCESS AND APPLICATION
ATE548382T1 (de) * 2007-09-04 2012-03-15 Biosteed Gene Expression Tech Co Ltd Polyethylenglykolmodifiziertes interferon alpha 2b und herstellungsverfahren und anwendungen davon
CA2720306C (en) * 2008-04-03 2016-03-15 Biosteed Gene Expression Tech. Co., Ltd. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
EP2113256A1 (en) 2008-04-29 2009-11-04 Ascendis Pharma AS PEGylated rhGH compounds
SI3050576T1 (sl) 2008-04-29 2021-08-31 Ascendis Pharma Endocrinology Division A/S Spojine pegiliranega rekombinantnega humanega rastnega hormona
DE102009009344B4 (de) * 2009-02-05 2018-01-04 Helmholtz-Zentrum Dresden - Rossendorf E.V. Verfahren und Anordnung zur Reinigung des Reaktionsgemisches bei der Herstellung von Radiopharmaka
EP2412730B1 (en) * 2009-03-27 2014-09-10 JW Pharmaceutical Corporation Interferon-alpha (ifn-alpha ) fused protein having ifn-alpha and cytoplasmic transduction peptide (ctp)
CN101514229B (zh) * 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物
CN106749608B (zh) * 2015-11-18 2021-10-15 石药集团中奇制药技术（石家庄）有限公司 干扰素α缀合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
EP1549332A4 (en) * 2002-09-05 2008-06-18 Gen Hospital Corp MODIFIED ASIALO-INTERFERONS AND USES THEREOF

Also Published As

Publication number Publication date
CA2503594C (en) 2011-05-10
AR042039A1 (es) 2005-06-08
MXPA05005178A (es) 2005-07-22
UY28080A1 (es) 2004-05-31
CN1323722C (zh) 2007-07-04
TW200413404A (en) 2004-08-01
AU2003293668A1 (en) 2004-06-15
CA2503594A1 (en) 2004-06-03
PA8587801A1 (es) 2004-09-16
ES2270152T3 (es) 2007-04-01
ATE337017T1 (de) 2006-09-15
NO20052310D0 (no) 2005-05-11
CN1711109A (zh) 2005-12-21
EP1562634B1 (en) 2006-08-23
ZA200503756B (en) 2008-02-27
JP4279258B2 (ja) 2009-06-17
RU2005118752A (ru) 2006-02-10
JP2006515571A (ja) 2006-06-01
DE60307881D1 (de) 2006-10-05
KR20050065677A (ko) 2005-06-29
NO20052310L (no) 2005-08-09
EP1562634A1 (en) 2005-08-17
BR0316227A (pt) 2005-10-04
GT200300244A (es) 2004-06-03
WO2004045648A1 (en) 2004-06-03
DE60307881T2 (de) 2007-03-08
US20040223950A1 (en) 2004-11-11
PL376883A1 (pl) 2006-01-09

Similar Documents

Publication Publication Date Title
PE20040834A1 (es) ISOMEROS POSICIONALES DEL IFN PEG ALFA 2a
CO5700785A2 (es) Composiciones inmunogenicas novedosas para la prevencion y el tratamiento de enfermedad meningococal
DK0409472T3 (da) Knoglemorfogenetisk protein
MX9207334A (es) Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
ES2160485B1 (es) Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
ES2124695T3 (es) Oligomeros, sus aplicaciones y formulaciones.
AR048912A1 (es) Inmunoglobulinas anti-nogo
ES2091906T3 (es) Composiciones que comprenden derivados de un peptido de omega-conotoxina y su uso en el tratamiento del daño neuronal relacionado con la isquemia.
ECSP066589A (es) Análogos oligonucleótidos clase c con potencia inmunoestimulante mejorada
AR045906A1 (es) Composicion farmaceutica para mejorar la solubilidad de farmacos hidrofobicos
MX9204685A (es) Secuencia de adn que codifica una proteina superficial externa (ospa) o derivado de la misma composicion de vacuna qe comprende tal proteina.
NO20034642L (no) Kondenserte bicykliske eller tricykliske aminosyrer
CL2003002043A1 (es) Compuestos derivados de tetrahidropiridina sustituidos en posicion 3 y 4; composicion farmaceutica, y sus usos en el tratamiento de enfermedades que estan asociadas con el sistema renina-angiotensina (ras), tales como hipertension, insuficiencia card
BR0305426A (pt) Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos
GT199800046A (es) Compuestos de pirazina.
AR073452A1 (es) Proteinas de fusion que comprende dos o mas antigenos de leishmania y su uso en el diagnostico y tratamiento de leishmaniasis
AR003589A1 (es) Utilizacion de una cantidad eficaz de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento destinada paratratar la inflamacion, y un procedimiento de tratamiento cosmetico mediante una composicion cosmetica que contiene a dicho peptido.
BR122012018280B8 (pt) composição farmacêutica compreendendo hormônio luteinizante humano e sacarose
ES2063383T3 (es) Vacunas contra la coccidiosis.
DK1219301T3 (da) Vacciner, som indeholder hybridpolypeptider, der består af mindst to forskellige allergene proteiner
ES2169037T3 (es) Conjugados polietilenglicol-hirudina, su procedimiento de preparacion y su empleo para el tratamiento de las trombosis.
AR038900A1 (es) Moleculas similares al interferon beta para el tratamiento del derrame cerebral
AR010400A1 (es) Purificacion de oxido de etileno por destilacion
ES2096368T3 (es) Quinolil-dihidropiridinas condensadas, procedimiento para su preparacion y su uso en medicamentos para el tratamiento de enfermedades cardiocirculatorias.
ES2145114T3 (es) Combinacion de atovacuona con proguanil para el tratamiento de infecciones protozoarias.

Legal Events

Date Code Title Description
FC Refusal